BIOXYNE LIMITED — Capital/Financing Update 2012

Feb 6, 2012

==> picture [218 x 51] intentionally omitted <==

==> picture [36 x 36] intentionally omitted <==

Probiomics Limited ABN 97 084 464 193 Suite 1A, Level 2 802 Pacific Highway Gordon NSW 2072

Australian Securities Exchange Limited Companies Announcements Office SYDNEY

P: +61 2 9844 5422 F: +61 2 9844 5445 W: www.probiomics.com.au

7 February, 2012

Correction in relation to Chairman’s Speech for General Meeting

I wish to advise the market of a correction that is required to be made to the text of the speech given by me to shareholders of the Company at a meeting this morning, and a copy of which has been published on the Company’s ASX platform.

Specifically, where I referred to Probiomics having:

• received valid acceptances under the Takeover Bid in respect of, inter alia, 76.94% of all Hunter Shares; and

• in addition , a relevant interest in 12.87% of Hunter Shares arising from a Pre-Bid Acceptance Agreement,

I should have advised the meeting that the 76.94% level of valid acceptances included the abovestated 12.87% relevant interest.

Accordingly, and for the sake of clarity, I advise that the total level of valid acceptances and relevant interest of Probiomics in Hunter Shares, as at close of business on 3 February, 2012, was 76.94%, and not 89.19%.

In addition, I advise that as at close of business on 6 February, 2012, the total level of valid acceptances and relevant interest of Probiomics in Hunter Shares was 79.11%.

==> picture [132 x 61] intentionally omitted <==

Patrick Ford

Non Executive Chairman

1

==> picture [218 x 51] intentionally omitted <==

==> picture [36 x 36] intentionally omitted <==

About Probiomics Limited

Probiomics has proprietary ownership of a unique probiotic strain – PCC[® ]

PCC[®] has been clinically proved to have superior qualities to other probiotic strains – particularly in promoting systemic immune response.

Probiomics’ commercial objective is to earn royalties from licensing PCC[®] to distribution companies selling products in global markets.

CONTACTS

Mr Ashok Jairath - Chief Financial Officer and Company Secretary Tel: 02 9844 5422

Email ashok.jairath@probiomics.com.au

2